Scope: To study the factors associated with mortality in hospitalized patients with community-acquired pneumonia treated with monotherapy or combination therapy. Methods: PubMed and Scopus were searched. Patients receiving macrolides, blactams and fluoroquinolones, as monotherapy or in combination, were included.
| INTRODUCTION
Community-acquired pneumonia (CAP) has been associated with significant mortality among hospitalized patients. 1 Appropriate antibiotic treatment is challenged by the emergence of resistant strains, including those of Streptococcus pneumoniae.
2,3 Treatment recommendations 1, [4] [5] [6] [7] [8] [9] are based on randomized controlled trials (RCTs) comparing monotherapy regimens in hospitalized patients with low mortality probability and on observational studies evaluating more severely ill patients than those enrolled in RCTs. 10, 11 Monotherapy and combination regimens are recommended for mild or moderate CAP; combination regimens are mainly recommended for severe CAP. Recent meta-analyses showed that macrolide therapy was associated with decreased mortality in critically ill patients with CAP, but not in those hospitalized in wards. 12, 13 However, in a meta-analysis of RCTs, there was no difference in mortality between fluoroquinolones (FQ) and b-lactam/macrolide (BL-M), despite improved Given the diversity of patients' characteristics and disease severity in CAP, the factors contributing to mortality according to specific treatment regimens should be explored. In addition, clinical and statistical heterogeneity among the available studies should be expected. In this context, we aimed to study systematically all available evidence regarding the comparative mortality between monotherapy and combination regimens in CAP patients. Using subgroup analyses and meta-regression, we attempted to explore factors that may contribute to different outcomes.
| METHODS

| Literature search and study selection process
The meta-analysis was not registered in any database. Literature search was conducted by 2 independent reviewers in PubMed and Scopus until November 2015. The search term was "(monotherapy OR combination therapy OR dual therapy OR macrolide OR quinolone OR b-lactam) and (community acquired pneumonia OR CAP) and (treatment OR management)." References of selected articles were hand-searched. Conference abstracts were not searched. The corresponding authors were contacted up to 3 times via e-mail requesting unpublished data. Only articles written in English were included. Data extraction was performed independently by 2 authors. Approval from the ethics committee was not required.
Any article reporting all-cause mortality according to the prescribed antibiotic therapy (single or dual antibiotic regimen) for adult patients hospitalized with CAP, regardless of pathogen and severity, was eligible. Cases were included only if treated with a b-lactam (BL), a fluoroquinolone or a macrolide, either alone or in combination. Patients receiving monotherapy with any other antibiotic (aminoglycosides, tetracyclines etc) alone or in combination were excluded. Studies on outpatients, hospital-acquired (HAP) or healthcare-associated pneumonia (HCAP) were excluded. Both randomized and nonrandomized trials were included; case reports and series (<10 patients) were ineligible.
| Definitions and outcomes
The primary outcome was all-cause mortality. Subgroup analyses according to specific antibiotic comparisons were performed as long as a combination regimen was included in one of the compared groups. Sensitivity analyses were performed according to study design, geographical region, period, time of mortality reporting (30-day, in-hospital, ICU) and in patients with bacteremia, septic shock or ICU admission. The definition of CAP was based on the definitions used in the individual studies. We excluded as many patients with HAP or HCAP as possible according to standard criteria. 15 
| Statistical analysis
The meta-analysis was performed with Review Manager for Windows (Review Manager (RevMan), version 5.2, Copenhagen: The Nordic Cochrane Centre, the Cochrane Collaboration, 2008). Pooled risk ratios (RR) and 95% confidence intervals (CI) were calculated using the random-effects model. Statistical heterogeneity among studies was assessed by chi-square test (P < .10 to indicate significant heterogeneity) and I 2 . Publication bias was assessed by visual inspection of the funnel plot. Univariate meta-regressions were planned to examine the impact of age, gender, ICU admissions, prior antibiotic use, nursing home residency, number of patients enrolled in the study, mortality in the included studies and comorbidity on the outcomes of the meta-analysis. Meta-regression was performed with the Metafor package for R, version 3.1.1 (R Core Team (2014). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria) using a mixedeffects model. Figure 1 shows the article selection process. Fifty articles provided mortality data and were included in the meta-analyses. Additional data were obtained by 12 investigators. 19, [23] [24] [25] 39, 41, [44] [45] [46] 50, 64 Table 1 shows the characteristics of the selected studies. Monotherapy (any regimen) was not associated with higher mortality than combination (any regimen, RR 1.14, 95% CI 0.99-1.32, I 2 84%). Publication bias was detected;
| RESULTS
small studies in favour of monotherapy regimens were underrepresented. Similar findings were observed after the exclusion of the 2 larger studies (1.11, 0.99-1.32). Table 2 summarizes the sensitivity analyses for mortality differences in patients treated with monotherapy and combination therapy. Thirty-day, in-hospital and ICU mortality was not different for monotherapy and combination. Monotherapy was associated with higher mortality in retrospective studies ( Figure 2 ) while both prospective studies and RCTs showed no difference in mortality. North American studies showed a higher mortality with monotherapy, which was vanished after the exclusion of the 2 larger studies ( were studied, there was no difference in mortality between monotherapy and combination. BL monotherapy was associated with higher mortality than BL-M combination (38 studies, 1.32, 1.12-1.56, I 2 85%). Publication bias towards small studies in favour of monotherapy regimens was detected. BL monotherapy was associated with higher mortality in all sensitivity analyses ( Table 3 ), besides that of patients treated in the ICU, studies performed before 1998 and RCTs. Considerable statistical heterogeneity was observed in these analyses. The between-group heterogeneity was not significant for study period and for mortality reporting time, but it was significant for study design and study place.
No difference in mortality between patients receiving FQ and BL-M was observed (27 studies, 0.98, 0.78-1.23, I 2 73%). Publication bias was not detected. Mortality was not different in almost all sensitivity analyses (Table 3) , besides the analysis of prospective studies. Heterogeneity varied in the individual sensitivity analyses (from none to considerable). The between-group heterogeneity was not significant for study place and period, but it was significant for study design (prospective studies showed significantly lower mortality for FQ, and retrospective studies showed a trend towards higher mortality for FQ) and for mortality reporting time.
Macrolide monotherapy was associated with lower mortality than BL-M (15 studies, 0.68, 0.51-0.92, I
2 32%), even after removing the 2 largest studies (0.59, 0.35-1.00, I 2 34%). In the sensitivity analyses (Table 3) , macrolides were associated with lower mortality than BL-M in studies reporting 30-day, but not in-hospital and in-ICU mortality and in both retrospective and prospective studies. A trend towards lower mortality was observed in North American and European studies and in studies initiated before and after 1998. Macrolides were associated with lower mortality in studies that included 1998, but the difference was not significant for studies performed entirely before or after 1998. Heterogeneity was present in few of the aforementioned subgroup analyses; the between-group heterogeneity was significant only for study design. 
| Meta-regression (monotherapy vs combination)
Several studies did not report data for all moderators. The moderators that could not account for the observed Articles identified in PubMed (n = 3276) and Scopus (n = 3811); additional search performed in article references
Articles excluded (n = 90) -Mortality not reported n = 12 -Antibiotic specific data for mortality not reported n = 57 -Pneumonia-specific data not available n = 5 -Studied other antibiotics n = 2 -Paediatric population n = 6 -Not English n = 3 -Duplicate publication n = 1 -Data on combination regimens only n = 4
Full-text articles assessed for eligibility after screening of title and/or abstract (n = 140)
Studies included in the meta-analysis and metaregression (n = 50) heterogeneity were age (P = .57); gender (P = .13); percentage of patients previously residing in nursing homes (P = .74), receiving antibiotics (P = .94) or requiring ICU care (P = .47) in each study; number of enrolled patients (P = .22); percentage of patients with lung disease (P = .80) or renal disease (P = .34); and mortality in each study (P = .99).
The moderators that could partially explain heterogeneity were heart disease, cancer and Pneumonia Severity Index (PSI) score IV. Although heart disease did not reach statistical significance (P = .08), when the percentage of included patients was higher than 30%, the probability of death increased by 30%. Regarding cancer, a frequency higher than 10% in the studied population increased the probability of death with monotherapy (P = .03; Figure 3 ). For a 15% frequency, the probability increased by 30%, while for a frequency of 35% the probability increased by 120%. The increase in the percentage of patients with PSI IV increased the mortality probability with monotherapy (P = .004; Figure 4 ), especially when it surpassed 65%. The inclusion of patients with PSI III and IV combined increased the probability of death only when the percentage of such patients in the study exceeded 90% (P = .034).
The influence of PSI score III on mortality with monotherapy was not significant (P = .26), as was that of PSI IV and V combined (P = .089). For all moderators, significant residual heterogeneity (P < .001) persisted. Meta-regressions for specific antibiotic comparisons were not performed as data from a sufficient number of studies was not available.
| DISCUSSION
Monotherapy was associated with a nonsignificant higher mortality than combination therapy; the observed difference was more pronounced in retrospective studies. Although North American studies showed higher mortality with monotherapy, the exclusion of 2 large registration studies resulted in indifference. BL was associated with higher mortality than BL-M, a difference that remained significant in most subgroup analyses; however, BL was not associated with higher mortality than BL-FQ. FQ were associated with lower mortality than BL-FQ, but a similar mortality to that of BL-M (only in prospective studies FQ were associated with lower mortality). These outcomes should be interpreted in view of the considerable heterogeneity, which persisted in most of the subgroup analyses, suggesting that the included studies were not necessarily comparable. Heterogeneity was lower or even vanished in analyses of RCTs, which included the lower number of studies and the less severely ill patients. Low-to-moderate heterogeneity was observed in the analysis comparing M with BL-M (patients receiving macrolides were in general younger and healthier).
T A B L E 2 Sensitivity analyses for monotherapy vs combination regimens
The percentage of patients with heart disease, cancer and mainly PSI score IV could partly account for the observed heterogeneity. Increasing cancer and heart disease frequency was associated with an increase in the probability of death with monotherapy. This could be due to higher probability of death thus prompting selection of monotherapy as palliative care, or higher probability for resistant pathogens and therefore inappropriate empirical treatment.
Increasing frequency of PSI IV patients in a study resulted in higher mortality probability with monotherapy. The influence of the percentage of patients with PSI scores III and IV on mortality with monotherapy was also statistically significant, but only when it was over 90%. Thus, based on the available evidence, it seems rational to analyse together the outcomes of patients with PSI score of I, II and probably III, but the inclusion of patients with higher probability for death (PSI IV and V) in the same analysis would probably distort the results. Therefore, investigators should probably consider not including patients with different PSI classes in future studies, or if they do, it would be desirable to provide the outcomes separately. As data for several of the other moderators were provided by only few of the included studies, it is possible that other patient characteristics might also influence outcomes and therefore require further study.
The findings of this meta-analysis are in general in accordance with the recommendations of published guidelines, besides that of BL-FQ (mainly administered to critically ill patients) and macrolide monotherapy. empirical regimens, intravenous or oral treatment (given the higher bioavailability of fluoroquinolones compared to b-lactams or macrolides). [68] [69] [70] [71] [72] the time to administration of the first dose, the implicated pathogens and their susceptibility to the administered antibiotics that could influence the outcomes were not available. 3 Confounding by indication cannot be ruled out, that is less severely ill patients were treated with monotherapy and more severely ill with combination. This analysis showed that macrolide monotherapy, a regimen not proposed in any of the published guidelines, was associated with lower mortality than BL-M. This finding is difficult to explain in an era of increasing resistance to macrolide antibiotics, especially for S. pneumoniae, unless we assume that confounding by indication is present. Indeed, in several of the included studies, macrolide monotherapy was administered in younger and at lower risk for death patients. 17, 21 Someone might argue that macrolides should have been appropriate at the early 1990s but will be inappropriate today due to increasing resistance and that the inclusion of older studies might have affected outcomes. However, older and newer studies had similar outcomes. Recent meta-analyses showed that therapy with macrolides was associated with decreased mortality in critically ill patients, but the benefit in those hospitalized in wards was minimal. 12, 13 Although valuable, a comparison of regimens containing or not an antibiotic may lead to false estimates, especially if confounding factors cannot be taken into account. The present meta-analysis provides a more precise estimation for specific regimens. The present analysis is limited by the few available data from RCTs, recruiting patients with mild-to-moderate CAP. In addition to the lack of interest from pharmaceutical companies due to the low antibiotic prices, the short administration period and the potential for development of resistance, several experts in the field believe that antibiotics may not be the mean to reduce further mortality in CAP. However, the role of adjunctive therapies is also debated. 73, 74 Second, the scope of most studies was not to compare patient outcomes according to the administered antibiotic regimens; unadjusted data for them were simply reported. Furthermore, communication with corresponding authors for unpublished data was not as successful as in other meta-analyses. Third, we included in the meta-analysis studies with different inclusion criteria and definition of CAP which might lead to potential biases. However, most of the studies enrolled mixed populations (admitted to the ICU or ward, bacteremic or not, pneumococcal or not, with variable severity). Specific data on mortality were not available for these subpopulations nor were provided upon request for the majority of the studies. Finally, although no formal assessment of the risk of bias and quality of studies was performed, it is expected that the overall quality (most studies did not control for confounding or did not provide baseline characteristics of studied populations) should be low to very low due to the almost absence of data from RCTs and high risk of bias. The currently available data are heterogeneous to support the recommendation of a specific antibiotic regimen over another. However, the study design and the characteristics of the population under study seem to influence the reported outcomes. Future studies should concentrate on more homogeneous populations in terms of disease severity and comorbidity. A meta-analysis of individual patient data may provide further useful insights. In view of studies showing that improvements in antibiotic selection have been among the factors contributing to a decrease in CAP mortality, 75, 76 well-designed RCTs are required to define the optimal antibiotic regimens for patients with moderate and severe CAP.
